Orion Biotech Opportunities Corp.
ORIA
NASDAQ Capital Market10.23
USD
- -
- -
CIK
0001847416
ISIN
KYG6780C1096
CUSIP
G6780C109
Return %
Stock
S&P500
1Y
4.71
26.53
3Y
6.56
76.60
5Y
6.56
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Zuie-Chin Huang
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 645 Fifth Avenue New York City NY United States of America 10022
- IPO Date
- Jul 2, 2021
- CIK
- 0001847416
- Similar Companies
- Business
- Orion Biotech Opportunities Corp. (Nasdaq: ORIA) operates as a blank check company whose primary business is pursuing a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities; it focuses primarily on opportunities in the biotechnology and life sciences industries. The company targets North American, European and Asian healthcare companies with potential to drive transformational change through novel therapies or technologies; it currently conducts no significant operations and generates no revenues. Founded in 2021 and headquartered in New York, New York, Orion Biotech Opportunities Corp. raised $200 million in its initial public offering in May 2021 underwritten by Cantor Fitzgerald. In recent developments, the company remains in search of a suitable target as its special purpose acquisition vehicle status persists without a completed business combination, while trading warrants (ORIAW) extend through April 2025; it faced auditor concerns over going-concern status in 2023 and subsequent delisting from the Nasdaq Composite Index amid unfulfilled merger activity.